These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 29327084)

  • 1. BACE1 inhibition more effectively suppresses initiation than progression of β-amyloid pathology.
    Peters F; Salihoglu H; Rodrigues E; Herzog E; Blume T; Filser S; Dorostkar M; Shimshek DR; Brose N; Neumann U; Herms J
    Acta Neuropathol; 2018 May; 135(5):695-710. PubMed ID: 29327084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of tau increase in cerebrospinal fluid of APP transgenic mice suggests downstream effect of BACE1 inhibition.
    Schelle J; Häsler LM; Göpfert JC; Joos TO; Vanderstichele H; Stoops E; Mandelkow EM; Neumann U; Shimshek DR; Staufenbiel M; Jucker M; Kaeser SA
    Alzheimers Dement; 2017 Jun; 13(6):701-709. PubMed ID: 27750032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in APP transgenic mice.
    Neumann U; Rueeger H; Machauer R; Veenstra SJ; Lueoend RM; Tintelnot-Blomley M; Laue G; Beltz K; Vogg B; Schmid P; Frieauff W; Shimshek DR; Staufenbiel M; Jacobson LH
    Mol Neurodegener; 2015 Sep; 10():44. PubMed ID: 26336937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brain pyroglutamate amyloid-β is produced by cathepsin B and is reduced by the cysteine protease inhibitor E64d, representing a potential Alzheimer's disease therapeutic.
    Hook G; Yu J; Toneff T; Kindy M; Hook V
    J Alzheimers Dis; 2014; 41(1):129-49. PubMed ID: 24595198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tau deletion reduces plaque-associated BACE1 accumulation and decelerates plaque formation in a mouse model of Alzheimer's disease.
    Peters F; Salihoglu H; Pratsch K; Herzog E; Pigoni M; Sgobio C; Lichtenthaler SF; Neumann U; Herms J
    EMBO J; 2019 Dec; 38(23):e102345. PubMed ID: 31701556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Presynaptic dystrophic neurites surrounding amyloid plaques are sites of microtubule disruption, BACE1 elevation, and increased Aβ generation in Alzheimer's disease.
    Sadleir KR; Kandalepas PC; Buggia-Prévot V; Nicholson DA; Thinakaran G; Vassar R
    Acta Neuropathol; 2016 Aug; 132(2):235-256. PubMed ID: 26993139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BACE1 elevation is involved in amyloid plaque development in the triple transgenic model of Alzheimer's disease: differential Aβ antibody labeling of early-onset axon terminal pathology.
    Cai Y; Zhang XM; Macklin LN; Cai H; Luo XG; Oddo S; Laferla FM; Struble RG; Rose GM; Patrylo PR; Yan XX
    Neurotox Res; 2012 Feb; 21(2):160-74. PubMed ID: 21725719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AZ-4217: a high potency BACE inhibitor displaying acute central efficacy in different in vivo models and reduced amyloid deposition in Tg2576 mice.
    Eketjäll S; Janson J; Jeppsson F; Svanhagen A; Kolmodin K; Gustavsson S; Radesäter AC; Eliason K; Briem S; Appelkvist P; Niva C; Berg AL; Karlström S; Swahn BM; Fälting J
    J Neurosci; 2013 Jun; 33(24):10075-84. PubMed ID: 23761903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beta-secretase-1 elevation in transgenic mouse models of Alzheimer's disease is associated with synaptic/axonal pathology and amyloidogenesis: implications for neuritic plaque development.
    Zhang XM; Cai Y; Xiong K; Cai H; Luo XG; Feng JC; Clough RW; Struble RG; Patrylo PR; Yan XX
    Eur J Neurosci; 2009 Dec; 30(12):2271-83. PubMed ID: 20092570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A noncompetitive BACE1 inhibitor TAK-070 ameliorates Abeta pathology and behavioral deficits in a mouse model of Alzheimer's disease.
    Fukumoto H; Takahashi H; Tarui N; Matsui J; Tomita T; Hirode M; Sagayama M; Maeda R; Kawamoto M; Hirai K; Terauchi J; Sakura Y; Kakihana M; Kato K; Iwatsubo T; Miyamoto M
    J Neurosci; 2010 Aug; 30(33):11157-66. PubMed ID: 20720123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calpain activation promotes BACE1 expression, amyloid precursor protein processing, and amyloid plaque formation in a transgenic mouse model of Alzheimer disease.
    Liang B; Duan BY; Zhou XP; Gong JX; Luo ZG
    J Biol Chem; 2010 Sep; 285(36):27737-44. PubMed ID: 20595388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor.
    May PC; Dean RA; Lowe SL; Martenyi F; Sheehan SM; Boggs LN; Monk SA; Mathes BM; Mergott DJ; Watson BM; Stout SL; Timm DE; Smith Labell E; Gonzales CR; Nakano M; Jhee SS; Yen M; Ereshefsky L; Lindstrom TD; Calligaro DO; Cocke PJ; Greg Hall D; Friedrich S; Citron M; Audia JE
    J Neurosci; 2011 Nov; 31(46):16507-16. PubMed ID: 22090477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Partial reduction of BACE1 improves synaptic plasticity, recent and remote memories in Alzheimer's disease transgenic mice.
    Kimura R; Devi L; Ohno M
    J Neurochem; 2010 Apr; 113(1):248-61. PubMed ID: 20089133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Centrally Delivered BACE1 Inhibitor Activates Microglia, and Reverses Amyloid Pathology and Cognitive Deficit in Aged Tg2576 Mice.
    Thakker DR; Sankaranarayanan S; Weatherspoon MR; Harrison J; Pierdomenico M; Heisel JM; Thompson LA; Haskell R; Grace JE; Taylor SJ; Albright CF; Shafer LL
    J Neurosci; 2015 Apr; 35(17):6931-6. PubMed ID: 25926467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphorylation of the translation initiation factor eIF2alpha increases BACE1 levels and promotes amyloidogenesis.
    O'Connor T; Sadleir KR; Maus E; Velliquette RA; Zhao J; Cole SL; Eimer WA; Hitt B; Bembinster LA; Lammich S; Lichtenthaler SF; Hébert SS; De Strooper B; Haass C; Bennett DA; Vassar R
    Neuron; 2008 Dec; 60(6):988-1009. PubMed ID: 19109907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between ubiquilin-1 and BACE1 in human Alzheimer's disease and APdE9 transgenic mouse brain and cell-based models.
    Natunen T; Takalo M; Kemppainen S; Leskelä S; Marttinen M; Kurkinen KMA; Pursiheimo JP; Sarajärvi T; Viswanathan J; Gabbouj S; Solje E; Tahvanainen E; Pirttimäki T; Kurki M; Paananen J; Rauramaa T; Miettinen P; Mäkinen P; Leinonen V; Soininen H; Airenne K; Tanzi RE; Tanila H; Haapasalo A; Hiltunen M
    Neurobiol Dis; 2016 Jan; 85():187-205. PubMed ID: 26563932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Astragaloside IV, a Natural PPARγ Agonist, Reduces Aβ Production in Alzheimer's Disease Through Inhibition of BACE1.
    Wang X; Wang Y; Hu JP; Yu S; Li BK; Cui Y; Ren L; Zhang LD
    Mol Neurobiol; 2017 May; 54(4):2939-2949. PubMed ID: 27023226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of chronic BACE1 inhibition in PS2APP mice depends on the regional Aβ deposition rate and plaque burden at treatment initiation.
    Brendel M; Jaworska A; Overhoff F; Blume T; Probst F; Gildehaus FJ; Bartenstein P; Haass C; Bohrmann B; Herms J; Willem M; Rominger A
    Theranostics; 2018; 8(18):4957-4968. PubMed ID: 30429879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beneficial effects of the β-secretase inhibitor GRL-8234 in 5XFAD Alzheimer's transgenic mice lessen during disease progression.
    Devi L; Tang J; Ohno M
    Curr Alzheimer Res; 2015; 12(1):13-21. PubMed ID: 25523425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cysteine protease inhibitor, E64d, reduces brain amyloid-β and improves memory deficits in Alzheimer's disease animal models by inhibiting cathepsin B, but not BACE1, β-secretase activity.
    Hook G; Hook V; Kindy M
    J Alzheimers Dis; 2011; 26(2):387-408. PubMed ID: 21613740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.